Directorio

Participants will receive the study drug in one eye during an outpatient surgery and will not need to stay in the hospital. Participation will last about 5 years and 5 months and includes 17 study visits, 1 phone visit, and regular tests and eye examinations.

This study is for breastfeeding women who are taking certain medicines as part of their regular medical care and for their breastfed babies. Participants may choose to provide samples of breast milk, blood from the mother, and blood from the baby. Researchers will use these samples to learn how these medicines move into breast milk and how much of the medicine may reach the baby during breastfeeding. The goal is to help doctors better understand the safety of these medicines for breastfeeding families.

We are doing this study to find out if an investigational drug called CA-4948 is a safe and effective option for people with PCNSL. We want to know how well it works when it is combined with a drug called ibrutinib, which is commonly used to treat PCNSL.

This study is testing a new way to guide a brain stimulation tool called TMS by using a camera to track a person's head. The goal is to do this without needing special headgear. Researchers hope this new method will make the treatment more comfortable and easier for people. They also want to see if it helps aim the tool more accurately, which could improve how well the treatment works.

We are doing this study to find out if an experimental drug called CT01681 (the study drug) is a safe and effective option for people who get CAR T-cell therapy as a treatment for diffuse large B cell lymphoma (DLBCL). We want to know if the study drug has the potential to lower or prevent certain side effects of CAR T-cell therapy. The possible side effects of CAR T-cell therapy that the study drug is being developed to protect against are called cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This study is enrolling people who will receive an available form of CAR T-cell therapy called YESCARTA.

We are doing this study to see if an experimental combination of drugs (D2C7-IT and 2141-V11) is a safe treatment for brain tumors.

The purpose of this study is to find out if giving two medicines, D2C7-IT and 2141-V11, directly into the part of the brain where the tumor is left after surgery is safe and works well. After that, patients will get regular shots of 2141-V11 under the skin near the lymph nodes in the head and neck. This study is for people who have a brain cancer called recurrent glioblastoma.